Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ALTERNATION: Everolimus-based CNI-free Immunosuppression After Liver Transplantation
NCT07739914Phase 3Recruiting
- Sponsor
- Hannover Medical School
- Start
- Aug 2026
- Primary completion
- Jun 2029
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of everolimus in liver transplantation (2 arms), sponsored by Hannover Medical School. Primary endpoint: Change from baseline in the estimated Glomerular Filtration Rate at 14 months. Started Aug 2026; status: recruiting.
02
Drugs
everolimus
03
Conditions
liver transplantation
Beyond the preview
Go deeper on NCT07739914.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07739914.